Calithera Financial Statements From 2010 to 2024
| CALADelisted Stock | USD 0.05 0.00 0.00% |
Check Calithera Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Calithera Biosciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Calithera financial statements analysis is a perfect complement when working with Calithera Biosciences Valuation or Volatility modules.
Calithera |
Calithera Biosciences Company Shares Outstanding Analysis
Calithera Biosciences' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Calithera Biosciences Shares Outstanding | 4.87 M |
Most of Calithera Biosciences' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Calithera Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Calithera Biosciences has 4.87 M of shares currently outstending. This is 97.3% lower than that of the Biotechnology sector and 95.44% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.15% higher than that of the company.
Calithera Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Calithera Biosciences's current stock value. Our valuation model uses many indicators to compare Calithera Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Calithera Biosciences competition to find correlations between indicators driving Calithera Biosciences's intrinsic value. More Info.Calithera Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Calithera Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Calithera Biosciences' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Calithera Biosciences Financial Statements
Calithera Biosciences stakeholders use historical fundamental indicators, such as Calithera Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Calithera Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Calithera Biosciences' assets and liabilities are reflected in the revenues and expenses on Calithera Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Calithera Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. Calithera Biosci operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 63 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Calithera Pink Sheet
If you are still planning to invest in Calithera Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calithera Biosciences' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |